pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$GPCRStructure Therapeutics Inc.

$GPCR17.36-4.46%
South San Francisco, CA, USupdated 19h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
aleniglipron l-arginine
Overweight

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Nov 5, 2026
earnings
$GPCR17.36-4.46%
14d ago
Structure Therapeutics Inc. earnings
Structure Therapeutics Inc.
→
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Structure Therapeutics Inc. jobs →

News

  • Why a fresh approach to targeting G protein-coupled receptors could treat a rare eye cancer
    Researchers found that only by targeting both the G protein-coupled receptor and its mutated internal molecular switch can uveal melanoma cell signaling be disrupted.
    fiercebiotech · 7d ago
  • Krazati withdrawal completed; Wegovy trial meets endpoint for kids ages 6 to 12
    Plus news about Structure Therapeutics, Cloverleaf Bio and Windward Bio. FDA finalizes Krazati withdrawal: Regulators officially finalized the drug’s withdrawal in second-line colorectal cancer las…
    endpoints · 2mo ago
  • Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
    Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s…
    biospace · 2mo ago
  • An AI drug specialist zeroes in on rare forms of obesity
    Superluminal Medicines banked $60 million in funding to support development of a drug designed to work similarly to — but potentially be more selectively than — Rhythm Pharmaceuticals’ marketed med…
    biopharma_dive · 2mo ago
  • Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
    Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on…
    biospace · 2mo ago
  • Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
    → Daiichi Sankyo will retool its commercial organization, and Ken Keller will be at the center of it all as chief commercialization officer. On April 1, 2027, the Japanese pharma will split the com…
    endpoints · 2mo ago
  • Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
    Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…
    biospace · 2mo ago
  • Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
    Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.
    biospace · 3mo ago
  • AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
    AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
    biospace · 3mo ago
  • AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
    AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
    biospace · 3mo ago
view all news mentions →
identifiers
ticker
$GPCR
SEC CIK
0001888886
country
US
source
sec_tickers
top tags
Obesity1Type 2 Diabetes1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 15m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?